Look Forward – Spring 2022 – Issue 176
This edition of Look Forward is packed full of details of our plans for 2022. There is so much going on and being able to get together in person is a big part of that.
Resources
From our newsletters to the recordings of our webinars and everything in-between, use the filters (below) to find the content that's right for you.
Luxturna, a gene therapy, is only for the treatment of Leber congenital amaurosis type 2 (LCA2) and severe early-onset RP caused by mutations in a specific gene called RPE65.